Status:
TERMINATED
An Investigational Scan (18F-Fluciclovine PET-CT) for the Measurement of Therapeutic Response in Patients With Metastatic Prostate Cancer
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Metastatic Prostate Carcinoma
Stage IVB Prostate Cancer AJCC v8
Eligibility:
MALE
18+ years
Phase:
PHASE4
Brief Summary
This phase IV trial studies how well an investigational scan (18F-fluciclovine PET-CT) works for the measurement of therapeutic response in patients with prostate cancer that has spread to other place...
Detailed Description
PRIMARY OBJECTIVE: I. Evaluate metabolic response by fluciclovine F18 (18F-fluciclovine) PET qualitatively and semi-quantitatively with standardized uptake values (SUV) following androgen deprivation...
Eligibility Criteria
Inclusion
- Histologically or cytologically proven prostate carcinoma
- Documented evidence of M1 disease by American Joint Committee on Cancer (AJCC) staging by bone scan, CT and magnetic resonance imaging (MRI)
- Castration naive disease, no prior systemic therapy for prostate cancer
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1
- Ability to understand and willingness to sign informed consent
Exclusion
- Known brain metastasis
- Small cell carcinoma of the prostate
Key Trial Info
Start Date :
September 19 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 28 2022
Estimated Enrollment :
2 Patients enrolled
Trial Details
Trial ID
NCT04134208
Start Date
September 19 2019
End Date
June 28 2022
Last Update
January 16 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
M D Anderson Cancer Center
Houston, Texas, United States, 77030